IP6K2 and prostate carcinoma: Similarly, enrichr19–21 analysis of genes deregulated upon enzalutamide treatment specifically in IP6K2 knockout cells, but not in wildtype cells (analyzed using edgeR22) identified several pathways related to mTORC1 and p53 signaling (e.g. mTOR Signaling and P53 Pathway) as well as pathways involving apoptosis and AR signaling (e.g. Positive Regulation of Apoptotic Signaling Pathway and Androgen Receptor/PSA Signaling in Prostate Cancer, respectively) (Fig. 5C and Supplementary Data 4).